Henderson Jane 4
4 · Apogee Therapeutics, Inc. · Filed Jan 6, 2026
Insider Transaction Report
Form 4
Henderson Jane
Chief Financial Officer
Transactions
- Sale
Common Stock
2026-01-02$74.13/sh−1,920$142,330→ 191,451 total - Sale
Common Stock
2026-01-02$75.20/sh−4,080$306,816→ 187,371 total - Sale
Common Stock
2026-01-06$80.00/sh−2,000$160,000→ 185,371 total - Award
Stock Option (Right to Buy)
2026-01-02+83,690→ 83,690 totalExercise: $75.78Exp: 2036-01-02→ Common Stock (83,690 underlying)
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.67 to $74.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.73 to $75.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.